BDSI - Long SetupSmall % insider buying late last year. Break 3.87 , Stop signal 3.47. Target 1 4.37, Target 2 Momentum
BDSI
BioDelivery Sciences (BDSI) - Long - 100 Percent Gain PotentialBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid-tolerant adult patients with cancer. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Sector: Health Care
Industry: Pharmaceuticals
Company Location: Raleigh
---12-month price targets---
High: $8.00
Mean: $6.96
Low: $5.50
BDSI LongI liked the price action here:
1) Increasingly large breakouts with pullbacks to prior level
2) Bullish megaphone pattern
3) Recent bullish wedge consolidation near resistance line
4) July '19 pullback consolidates atop July '17 top
BDSI sells buprenorphine formulations for pain management and opioid dependence management. Most recent quarter was a huge revenue beat and guidance raise.
